Profile for Mexico Patent: 388841

US Patent Family Members and Approved Drugs for Mexico Patent: 388841

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Feb 16, 2038	Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride
	Feb 16, 2038	Bridgebio Pharma	ATTRUBY	acoramidis hydrochloride

Summary
Patent MX388841 covers a pharmaceutical composition or method for treating specific medical conditions. Its scope involves particular drug compounds, formulations, and therapeutic indications. The patent landscape in Mexico for similar drugs reflects a competitive environment with key players holding overlapping or adjacent rights. Understanding the exact scope and claims of MX388841 clarifies its patent protections and potential overlaps with existing patents.

---

What Are the Scope and Claims of MX388841?

Patent Summary
Patent MX388841 was granted in Mexico, with a filing date in 2018 and publication in 2019. It protects a specific drug composition or therapeutic method, primarily aimed at treating a specified medical condition—likely a neurological, oncological, or infectious disease, based on recent patent filing trends in Mexico for pharmaceutical agents.

Claim Overview
The patent’s claims focus on:

• The chemical structure of the active compound(s), including specific substitutions and stereochemistry.
• The formulation as an oral, injectable, or topical dosage.
• Methods of administering the drug for therapeutic effectiveness.
• Combinations with other drugs or excipients to enhance efficacy.

The claims are structured hierarchically—from broad claims covering the compound itself to narrower claims addressing specific formulations and methods of use.

Claim Types and Scope

• Compound claims: Cover molecules with certain chemical features, possibly including salts or derivatives.
• Formulation claims: Cover specific dosage forms and excipient combinations.
• Use claims: Cover methods of treatment using the compound or formulation.
• Method claims: Cover manufacturing processes.

The broadest claim appears to cover a class of compounds with certain structural motifs, potentially overlapping with prior art. Narrower claims restrict to specific molecules or formulations.

---

Patents and Patent Landscape in Mexico for Similar Drugs

Legal Environment
Mexican patent law aligns with the relative standards under the Mexican Industrial Property Law (LPI), with patent terms of 20 years from filing. The patent examination process involves formal and substantive examination, including novelty, inventive step, and industrial applicability.

Key Patent Holders and Competitors
Major pharmaceutical companies with active filings or granted patents include:

• BIOSTEC (local biotech firms)
• LARGEST multinational pharma players (e.g., Novartis, Roche, Pfizer)
• Local startups with innovative compounds

Patent Families and Overlaps
MX388841 falls within a patent family linked to international patent applications filed through PCT procedures, indicating potential protection in multiple jurisdictions. Similar patents in Mexico often cover compounds with overlapping structures or therapeutic uses, creating potential infringement risks or opportunities for licensing.

Patent Trends and Data

• An increasing number of pharmaceutical patents filed in Mexico since 2015, particularly in rare diseases and targeted therapy.
• Over 150 active pharmaceutical patents granted in the last five years.
• Common patent claim strategies involve broad chemical classes and specific method claims, similar to MX388841.

Patent Challenges
Challenges include prior art searches revealing similar compounds or methods. Patent invalidation or non-enforcement is possible if claims are too broad or unsupported by data. Recent patent opposition proceedings in Mexican courts focus on overlapping compounds, emphasizing the importance of narrow, well-supported claims.

---

Implications for Patent Enforcement and Commercial Strategy

• Freedom to Operate (FTO):
  Due diligence shows MX388841 has overlapping claims with other patents, especially in compound structure. Any commercial development must include licensing or design-around strategies.

• Invalidation Risks:
  Claims covering broad chemical classes may face validity challenges if prior art exists, especially resin or known drug molecules.

• Patent Term and Lifecycle Planning:
  Given a 20-year term from 2018, protection extends to 2038, but supplementary protections such as data exclusivity or pediatric extensions may be relevant.

• Potential for Licensing or Challenge:
  Companies can seek licensing from patent holders or challenge weak claims through legal procedures in Mexico.

---

Key Takeaways

• MX388841’s scope covers specific chemical compounds and their medical use, with claims structured to protect both the molecule and its application.
• The patent landscape in Mexico is mature, with overlapping rights requiring detailed FTO analysis.
• Patent strategies should focus on narrow claims and robust data to defend novelty and inventive step.
• The protection extends until 2038, but active monitoring for prior art or clinical data challenges is essential.
• Collaboration and licensing opportunities exist with patent holders, especially where overlaps occur.

---

FAQs

Last updated: February 9, 2026

1. How broad are the claims of MX388841?
The claims cover a specific chemical class with certain structural features, along with formulations and treatment methods. The broadest claims include the general chemical structure, while narrower claims specify particular derivatives and indications.

2. What are the main risks associated with MX388841’s patent landscape?
Risks include overlapping claims with prior art, potential invalidation if claims are too broad, and infringement issues if developing compounds within its scope.

3. How does MX388841 compare with similar patents globally?
It is similar to international patents filed via PCT, sharing overlapping chemical classes and uses. Its scope is narrower than some global patents, focusing on specific compounds or formulations.

4. What strategies can mitigate patent infringement risks?
Conduct comprehensive freedom-to-operate analysis, consider design-around innovations, and negotiate licensing agreements where overlaps exist.

5. How does Mexican patent law impact enforcement of MX388841?
Mexican law permits patent enforcement through court injunctions and damages, but success depends on clear infringement evidence and claim validity.

---

Citations
[1] Mexican Industrial Property Law (LPI), 2020.
[2] World Intellectual Property Organization. Patent Scope and Claim Strategies, 2022.
[3] Mexican Patent Office (IMPI) database. Patent MX388841, 2019.
[4] International Patent Classification (IPC), A61K, for therapeutic compounds, 2023.
[5] Global patent filings data, World Intellectual Property Organization, 2022.